Author

Anke Kleine-Tebbe

Observed names: A Kleine-Tebbe, A. Kleine-Tebbe, A. Kleine‐Tebbe, Kleine-Tebbe, Anke

Observed institutions: University of Cologne, Universität Ulm, Helios Dr. Horst Schmidt Kliniken Wiesbaden, German Red Cross, Medizinische Hochschule Hannover, Humboldt-Universität zu Berlin, Universitätsklinikum Erlangen, Universitätsklinik Marien Hospital Herne, SRH Wald-Klinikum Gera, National Center for Tumor Diseases, Luisenkrankenhaus, Universitätsmedizin Göttingen, Klinikum Frankfurt Höchst, Universitäts Frauenklinik, DRK Kliniken Berlin, University Hospital Magdeburg, Klinikum Sindelfingen-Böblingen, Women‘s Healthcare Group, Kliniken Essen-Mitte, Rotkreuzklinikum München, Comprehensive Cancer Center Erlangen, University Hospital Cologne, University Hospital Ulm, Helios Hospital Berlin-Buch, Stiftung Charité, Pathologisches Institut, Heinrich Heine University Düsseldorf, Martin Luther University Halle-Wittenberg, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München

OpenAlex ID: A5085624728

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism

2013 · Jan Budczies, Scarlet F. Brockmöller, et al. · Journal of Proteomics · 175

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor–Positive Phase II Randomized Trial—Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET

2017 · Nadia Harbeck, Oleg Gluz, et al. · Journal of Clinical Oncology · 147

Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes

2007 · Gerhard Schaller, Ilka Fuchs, et al. · Journal of Clinical Oncology · 99

PDF

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

2022 · Ulrike Nitz, Oleg Gluz, et al. · The Lancet Oncology · 92

The prognostic significance of epithelial-mesenchymal transition in breast cancer.

2003 · Ilka B Fuchs, Werner Lichtenegger, et al. · PubMed · 75

Analysis of PIK3CA Mutations in Breast Cancer Subtypes

2013 · Ruza Arsenic, Annika Lehmann, et al. · Applied immunohistochemistry & molecular morphology · 61

Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy – A phase II-study

2011 · Gero Wieners, Konrad Mohnike, et al. · Radiotherapy and Oncology · 57

Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers

2022 · O. Ortmann, J.-U. Blohmer, et al. · Journal of Cancer Research and Clinical Oncology · 53

PDF

Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer

2021 · R. Charles Coombes, Holly Tovey, et al. · JAMA Oncology · 50

PDF

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

2010 · M. Kaufmann, N. Maass, et al. · European Journal of Cancer · 39

Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)

2003 · Ilka B. Fuchs, Solveig Landt, et al. · Breast Cancer Research and Treatment · 37

Analysis of quantitative changes in hair growth during treatment with chemotherapy or tamoxifen in patients with breast cancer: a cohort study

2013 · V. Kanti, R. Nuwayhid, et al. · British Journal of Dermatology · 36

Role of the Major Allergen (Fel d I) in Patients Sensitized to Cat Allergens

2009 · J. Kleine-Tebbe, Anke Kleine-Tebbe, et al. · International Archives of Allergy and Immunology · 36

Abstract S5-03: Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer

2016 · N Harbeck, O Gluz, et al. · Cancer Research · 29

Type I sensitization towards patent blue as a cause of anaphylaxis

2003 · K. Forschner, A. Kleine‐Tebbe, et al. · Allergy · 24

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial

2010 · J.-U. Blohmer, P. Schmid, et al. · Annals of Oncology · 22

Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer

2005 · G. Schaller, N. Bangemann, et al. · Journal of Clinical Oncology · 19

Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

2015 · Nadia Harbeck, Oleg Gluz, et al. · Journal of Clinical Oncology · 18

Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer

2014 · Johannes Wohlrab, Nikola Bangemann, et al. · Breast Cancer Targets and Therapy · 17

PDF

Multicentric reticulohistiocytosis indicating metastasis of an unknown primary tumour

1998 · M Worm, A Kleine-Tebbe, et al. · Acta Dermato Venereologica · 15

Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients

2015 · V. Kanti, R. Nuwayhid, et al. · Journal of the European Academy of Dermatology and Venereology · 12

Safety and efficacy of first-line epirubicin–docetaxel (ED) versus epirubicin–cyclophosphamide (EC): A multicenter randomized phase III trial in metastatic breast cancer (MBC)

2004 · J.-U. Blohmer, M. Hauschild, et al. · Journal of Clinical Oncology · 9

Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment

2009 · J. Huober, G. von Minckwitz, et al. · Journal of Clinical Oncology · 7

Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study

2025 · Thorsten Kühn, Maggie Banys-Paluchowski, et al. · British journal of surgery · 6

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer

2026 · P.A. Francis, P.A. Francis, et al. · Annals of Oncology · 4

Works count: 61

Citation count: 1,155

H-index: 18

I10-index: 21